Thomson Reuters, a US-based provider of information for businesses and professionals, has announced the launch of BIOMARKERcenter, a unique comprehensive resource for biomarker intelligence. The new solution claims to be the first to provide the pharmaceutical industry with a framework for assessing the potential of a biomarker and to be alerted of any changes in their status.
BIOMARKERcenter covers the biomarkers identified in literature, patents, conferences, clinical trial information, and other sources for all major therapeutic areas including oncology, cardiovascular diseases, diabetes, respiratory disorders, autoimmune diseases and neurological disorders. For each therapy area, it includes not only biomarkers with established clinical usage, but also emerging uses for the biomarker.
Each record has been manually created by a team of Thomson Reuters experts and provides a unique report on the biomarker using a novel lifecycle model. Other data provided will include the name, classification, biological entities/processes involved, associated drugs, role or utilities, measurement techniques, regulatory status and related diagnostic kits.
Biomarkers are measurable indicators which can be used to define a biological state. Using Biomarkers as part of a pharmaceutical R&D programme can increase the success of the project by encouraging innovation, improving efficiency, saving costs and delivering a valuable advantage over competitors.
The new solution will be available as a standalone web solution, fully integrated into Prous Science's Integrity platform, or as an XML feed to internal customer databases. The Integrity integration and XML feed are available currently, with the standalone solution to be delivered later in 2008.
